Takara Bio Inc.
4974.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.23 | -0.87 | -0.67 | 0.13 |
| FCF Yield | -4.04% | -9.51% | 14.86% | -2.06% |
| EV / EBITDA | 10.96 | 10.65 | 6.18 | 7.85 |
| Quality | ||||
| ROIC | 1.04% | 1.37% | 13.49% | 21.19% |
| Gross Margin | 57.88% | 61.85% | 57.29% | 72.69% |
| Cash Conversion Ratio | 5.61 | 1.16 | 1.74 | 0.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.78% | -13.70% | 19.24% | 25.12% |
| Free Cash Flow Growth | 63.61% | -135.68% | 658.43% | -208.94% |
| Safety | ||||
| Net Debt / EBITDA | -4.38 | -4.08 | -1.85 | -0.67 |
| Interest Coverage | 113.15 | 130.57 | 855.88 | 1,256.61 |
| Efficiency | ||||
| Inventory Turnover | 1.53 | 1.40 | 3.01 | 0.77 |
| Cash Conversion Cycle | 321.12 | 321.35 | 153.98 | 532.42 |